Practical Considerations for APOL1 Genotyping in the Living Kidney Donor Evaluation

Background. Association between the apolipoprotein L1 gene (APOL1) and nephropathy has altered the epidemiology of chronic kidney disease. In addition, donor APOL1 genotypes play important roles in the time to allograft failure in kidneys transplanted from deceased donors and the safety of living kidney donation. Methods. This article reviews genetic testing for inherited kidney disease in living kidney donors to improve donor safety. APOL1 genotyping in donors with recent African ancestry is considered. Results. Based on current data, transplant physicians should discuss APOL1 genotyping with potential living kidney donors self-reporting recent African ancestry. Until results from APOL1 Long-term Kidney Transplant Outcomes Network ancillary studies are available, we present practical approaches from our experience for considering APOL1 genotyping in the living donor evaluation. Conclusions. Transplant physicians should inform potential living kidney donors at risk for APOL1-associated nephropathy about the gene and possibility of genetic testing early in the donor evaluation, well before scheduling the donor nephrectomy. Transplant programs must weigh risks of performing a donor nephrectomy in those with 2 APOL1 renal risk variants (high-risk genotypes), particularly younger individuals. Our program counsels kidney donors with APOL1 high-risk genotypes in the same fashion as with risk genotypes in other nephropathy genes. Because most African American kidney donor candidates lacking hypertension, proteinuria and reduced kidney function after workup will not possess APOL1 high-risk genotypes, genetic testing is unlikely to markedly increase donor declines and may reassure donors with regard to their long-term kidney outcomes, potentially increasing the number of African American donors.

[1]  A. Iltis,et al.  APOL1 Genetic Testing in Living Kidney Transplant Donors. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  D. Segev,et al.  The changing landscape of live kidney donation in the United States from 2005 to 2017 , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  Christopher E. Hart,et al.  Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic mice. , 2019, JCI insight.

[4]  D. Segev,et al.  Risks of Living Kidney Donation: Current State of Knowledge on Outcomes Important to Donors. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[5]  O. Gribouval,et al.  WITHDRAWN: APOL1 risk genotype in Europe: Data in patients with focal segmental glomerulosclerosis and after renal transplantation. , 2019, Nephrologie & therapeutique.

[6]  S. Fullerton,et al.  You Are Just Now Telling Us About This? African American Perspectives of Testing for Genetic Susceptibility to Kidney Disease. , 2019, Journal of the American Society of Nephrology : JASN.

[7]  Cristian Riella,et al.  APOL1-Associated Kidney Disease in Brazil , 2019, Kidney international reports.

[8]  E. Gordon,et al.  A National Survey of Transplant Surgeons and Nephrologists on Implementing Apolipoprotein L1 (APOL1) Genetic Testing Into Clinical Practice , 2018, Progress in transplantation.

[9]  E. Gordon,et al.  African American Living Donors' Attitudes About APOL1 Genetic Testing: A Mixed Methods Study. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  B. Freedman,et al.  The APOL1 Long-Term Kidney Transplantation Outcomes Network-APOLLO. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[11]  Jie Ding,et al.  Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group. , 2018, Kidney international.

[12]  A. Garg,et al.  APOL1 Genotype and Renal Function of Black Living Donors. , 2018, Journal of the American Society of Nephrology : JASN.

[13]  B. Freedman,et al.  Evaluation of Potential Living Kidney Donors in the APOL1 Era. , 2018, Journal of the American Society of Nephrology : JASN.

[14]  D. Klassen,et al.  Risk of ESRD in prior living kidney donors , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  F. Cigarroa,et al.  Disparities in Live Donor Kidney Transplantation: Related to Poverty, Race, or Ethnicity? , 2018, JAMA.

[16]  B. Freedman,et al.  Need to Reclassify Etiologies of ESRD on the CMS 2728 Medical Evidence Report. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[17]  S. Fullerton,et al.  Clinical Genetic Testing for APOL1: Are we There Yet? , 2017, Seminars in nephrology.

[18]  S. Chadban,et al.  Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes. , 2017, Kidney international.

[19]  A. Garg,et al.  Summary of Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors , 2017, Transplantation.

[20]  A. Reiner,et al.  Sickle Cell Trait and the Risk of ESRD in Blacks. , 2017, Journal of the American Society of Nephrology : JASN.

[21]  A. Israni,et al.  Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  J. Schold,et al.  Integrating APOL1 Gene Variants Into Renal Transplantation: Considerations Arising From the American Society of Transplantation Expert Conference , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  A. Kwitek,et al.  Screening of Living Kidney Donors for Genetic Diseases Using a Comprehensive Genetic Testing Strategy , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  E. Gordon,et al.  APOL1‐Associated End‐Stage Renal Disease in a Living Kidney Transplant Donor , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  J. Rodrigue,et al.  Health Insurance Trends in United States Living Kidney Donors (2004 to 2015) , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  L. Ross,et al.  Introducing Genetic Tests With Uncertain Implications in Living Donor Kidney Transplantation , 2016, Progress in transplantation.

[27]  A. Garg,et al.  Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate. , 2016, The New England journal of medicine.

[28]  Nicholette D. Palmer,et al.  APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors , 2016, Transplantation.

[29]  A. Garg,et al.  Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate. , 2016, The New England journal of medicine.

[30]  K. Dahan,et al.  Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management--A KDIGO consensus report. , 2015, Kidney international.

[31]  L. Riella,et al.  Testing for High-Risk APOL1 Alleles in Potential Living Kidney Donors. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  A. Garg,et al.  Race, Relationship and Renal Diagnoses After Living Kidney Donation , 2015, Transplantation.

[33]  Nicholette D. Palmer,et al.  Apolipoprotein L1 Gene Variants in Deceased Organ Donors Are Associated With Renal Allograft Failure , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[34]  R. Simms,et al.  Genetic Testing in the Assessment of Living Related Kidney Donors at Risk of Autosomal Dominant Polycystic Kidney Disease , 2015, Transplantation.

[35]  M. Ramsay,et al.  APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans. , 2015, Journal of the American Society of Nephrology : JASN.

[36]  M. Haider,et al.  Imaging-based diagnosis of autosomal dominant polycystic kidney disease. , 2015, Journal of the American Society of Nephrology : JASN.

[37]  K. Skorecki,et al.  Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[38]  J. George,et al.  Syndromes of thrombotic microangiopathy. , 2014, The New England journal of medicine.

[39]  Leslie G Biesecker,et al.  Diagnostic clinical genome and exome sequencing. , 2014, The New England journal of medicine.

[40]  O. Gribouval,et al.  APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  M. Barua,et al.  Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing , 2014, Kidney international.

[42]  Mei-Cheng Wang,et al.  Risk of end-stage renal disease following live kidney donation. , 2014, JAMA.

[43]  Richard J. H. Smith,et al.  Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. , 2014, Journal of the American Society of Nephrology : JASN.

[44]  B. Freedman,et al.  Perceptions regarding Genetic Testing in Populations at Risk for Nephropathy , 2013, American Journal of Nephrology.

[45]  V. D’Agati,et al.  The modern spectrum of renal biopsy findings in patients with diabetes. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[46]  M. Ognjanović,et al.  Simultaneous sequencing of 24 genes associated with steroid-resistant nephrotic syndrome. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[47]  B. Eckloff,et al.  Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. , 2012, Journal of the American Society of Nephrology : JASN.

[48]  C. Langefeld,et al.  Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[49]  C. Young,et al.  African American living-kidney donors should be screened for APOL1 risk alleles. , 2011, Transplantation.

[50]  C. Young,et al.  Ethnic and Gender Related Differences in the Risk of End‐Stage Renal Disease After Living Kidney Donation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[51]  M. Rocco,et al.  The APOL1 Gene and Allograft Survival after Kidney Transplantation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[52]  M. Schnitzler,et al.  Racial variation in medical outcomes among living kidney donors. , 2010, The New England journal of medicine.

[53]  C. Winkler,et al.  Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans , 2010, Science.

[54]  S. Rosset,et al.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene , 2010, Human Genetics.

[55]  R. Montgomery,et al.  DNA Testing for Live Kidney Donors at Risk for Autosomal Dominant Polycystic Kidney Disease , 2009, Transplantation.

[56]  B. Freedman,et al.  The familial risk of end-stage renal disease in African Americans. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.